Compare STOK & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STOK | TSLX |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2019 | 2014 |
| Metric | STOK | TSLX |
|---|---|---|
| Price | $27.86 | $22.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $34.50 | $23.50 |
| AVG Volume (30 Days) | ★ 812.5K | 430.3K |
| Earning Date | 11-04-2025 | 02-12-2026 |
| Dividend Yield | N/A | ★ 9.19% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.68 | ★ 2.04 |
| Revenue | $205,632,000.00 | ★ $464,512,000.00 |
| Revenue This Year | $430.24 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $41.92 | ★ $10.92 |
| Revenue Growth | ★ 1128.17 | N/A |
| 52 Week Low | $5.35 | $18.58 |
| 52 Week High | $38.69 | $25.17 |
| Indicator | STOK | TSLX |
|---|---|---|
| Relative Strength Index (RSI) | 40.11 | 53.76 |
| Support Level | $25.21 | $21.11 |
| Resistance Level | $31.70 | $22.47 |
| Average True Range (ATR) | 2.09 | 0.44 |
| MACD | -0.58 | 0.07 |
| Stochastic Oscillator | 27.86 | 74.63 |
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.